Plain-English translation of NCT05702853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new version of CD19 CAR T-cell therapy—a treatment that uses your own immune cells, genetically modified to recognize and attack cancer cells. The researchers have made two key improvements to this therapy: they've added a special marker to help purify the cells (removing non-cancer-fighting cells), and they've changed how the cells are prepared to make them stronger and longer-lasting. The goal is to create a more effective and safer treatment for blood cancers that haven't responded to standard treatments.
Current CAR T-cell therapy works for many patients, but some patients relapse (cancer comes back), and the treatment can cause serious side effects. This trial exists to improve the therapy by making the cells purer, stronger, and more persistent so they can fight cancer more effectively while causing fewer harmful side effects.
You likely qualify if…
You likely don't qualify if…
You will first undergo screening tests including blood work and scans to confirm you are eligible. If accepted, your T cells will be collected through a procedure called leukapheresis (similar to donating blood plasma). Your cells will then be sent to a lab where they are genetically modified and specially prepared over several weeks. You will receive chemotherapy to prepare your body, then the engineered cells will be infused back into you. You will need close monitoring with frequent clinic visits and blood tests during the first months to watch for side effects and how well the treatment is working.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States